Sarcoidosis: can tofacitinib slay the dragon?
Nat Rev Rheumatol
.
2022 Oct;18(10):557-558.
doi: 10.1038/s41584-022-00832-1.
Authors
Nadera J Sweiss
1
,
Robert Baughman
2
Affiliations
1
Division of Rheumatology, University of Illinois, Chicago, IL, USA. nsweiss@uic.edu.
2
Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
PMID:
35999390
DOI:
10.1038/s41584-022-00832-1
No abstract available
Publication types
Comment
MeSH terms
Humans
Menthol
Piperidines / therapeutic use
Pyrimidines / adverse effects
Sarcoidosis* / drug therapy
Substances
Piperidines
Pyrimidines
Menthol
tofacitinib